Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaSunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsThe design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agentsAntiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondMonitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinomaRandomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.Targeting angiogenesis in metastatic breast cancerEvaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.The potential of sunitinib as a therapy in ovarian cancer.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
P2860
Q26747666-C6FB720F-796B-4BAF-BE14-F37A6C839D48Q33393174-D0B8EC87-9ABB-41F7-B9A9-99EEFE2CCABEQ33872751-D67FBEF9-8713-4A0E-BE72-70B3A0D3E831Q34854658-98B4B8D2-E242-4FA2-B440-A95080B1B2A0Q35660763-70801D85-D846-4B5C-821F-8399B290B4A4Q35703904-DCC743EB-6278-4213-A144-707CDF6BE659Q35927364-F4B0E7E6-69A4-4A2D-ACFA-2DFDE8DF3760Q36182795-B314A224-ED77-401F-87DA-58FD0D0D854DQ37624187-5917D5D1-25D1-46BB-98A0-4DFF92B8E733Q38014533-6D958BA7-4C3D-4824-A644-E5FB6DED7641Q38144166-7A6F5B79-43B5-4DF3-99F6-731CCA67592DQ38552109-B7470E6E-8466-4757-9C5B-15B2F211BA02Q39499521-DF79ED7F-A061-4A8C-856A-F70C17A878FAQ43841175-EA011F4A-8A2F-401E-B6D0-CA5CF04F61DFQ47957959-DBFC3278-1BED-45FC-B492-71B0057F1654Q54563946-018BD418-553D-4F5E-B0F1-CF6CACF5B2CD
P2860
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Sunitinib in combination with ...... phase I dose-escalation study
@ast
Sunitinib in combination with ...... phase I dose-escalation study
@en
type
label
Sunitinib in combination with ...... phase I dose-escalation study
@ast
Sunitinib in combination with ...... phase I dose-escalation study
@en
prefLabel
Sunitinib in combination with ...... phase I dose-escalation study
@ast
Sunitinib in combination with ...... phase I dose-escalation study
@en
P2093
P2860
P1476
Sunitinib in combination with ...... phase I dose-escalation study
@en
P2093
Alan Sandler
Anne M Traynor
Francisco Robert
Jennifer Ilagan
Joan H Schiller
Karen Harper
Lesley Tye
Richard Chao
P2860
P2888
P304
P356
10.1007/S00280-009-1209-0
P577
2009-12-31T00:00:00Z
P5875
P6179
1025389146